Gene therapy is making great strides: Gene therapy involves the insertion of copies ofhealthy genes into a patient’s genetic code to counteract the effect of mutated or missing genes that can cause genetic disorders and illnesses. The genes can be injected directly into cells. The technique has courted controversy, and only received regulatory approval in the US in 2017 after years of research and development. It has mostly been used to help patients fighting cancer, but a version of the therapy recently developed by Bluebird Bio has shown some promise in curing a teenage boy in France of sickle cell disease. Meanwhile, another form of the treatment — known as Kymriah and Yescarta — has sent patients in the US with bone marrow cancer and lymphoma into long term remission.
More from Enterprise
The CBE is taking a tougher stance on regulation
Last summer, HSBC paid the CBE a EGP 1.4 bn…
Farmers aren’t borrowing to survive anymore — they’re investing
Medium-term loans rose more than 1k% to EGP 22.6 bn…
Why do listed companies buy back treasury shares?
Dividends are subject to a 10% withholding tax, while buybacks…
Valu gets regulatory green light to start operations in Jordan
Former Jordanian Investment Minister Mothanna Gharaibeh will serve as chairman…